Skip to content

Quantum Dots for Medicine Current Applications, Challenges, and Future Directions - A Comprehensive Review

FieldValue
JournalZenodo (CERN European Organization for Nuclear Research)
Published2026-04-23
AuthorsAbhinav Dupare*, Nitin Padole, Pankaj Dhapke , Nilakshi Dhoble, Jagdish Baheti
DOI10.5281/zenodo.19703488

Quantum dots have not yet crossed from preclinical development into routine clinical use, according to the review. The authors identify multiplexed diagnostics and targeted therapy as the main application areas. They also cover drug and gene delivery, photothermal and photodynamic treatment, and combined imaging and therapy. Clinical translation remains blocked by long-term toxicity, uncertain biodistribution and clearance, batch variability, manufacturing scale, and regulatory gaps. The review’s strongest quantitative result is a material size rather than a clinical effect size. Semiconductor quantum dots are generally 1 to 10 nm. The review reports no shared detection limit, quantum yield, therapeutic response, or clinical endpoint across the studies it discusses.

Material classes and size-dependent behavior

Section titled “Material classes and size-dependent behavior”

Quantum confinement links discrete carrier energy levels to nanometer-scale size. Smaller semiconductor dots shift excitation peaks toward shorter wavelengths and allow fluorescence tuning by size. Semiconductor quantum dots are generally 1 to 10 nm CdSe, CdTe, ZnS, or InP nanocrystals. Polymer, silica-shell, or lipid coatings are used to disperse them in biological media. Antibodies, peptides, aptamers, or small molecules then provide targeting.

Material classReported sizeOptical or sensing propertyBiomedical roleMain limitation
Semiconductor quantum dots1 to 10 nmTunable fluorescence, narrow bands, high photostabilityImmunoassays, imaging, photodynamic and photothermal therapyHeavy-metal toxicity and retention
Carbon quantum dotsLess than 10 nmMetal-free fluorescence and high water solubilityBiosensing, cell imaging, drug deliveryLower brightness than semiconductor quantum dots
Graphene quantum dotsLess than 20 nmNear-infrared absorption and photothermal conversionBiosensing and cancer theranosticsStability and batch variability
Black phosphorus quantum dots2 to 10 nmNear-infrared absorption and high photothermal efficiencyCancer phototherapyOxidation and chemical instability
Perovskite quantum dots5 to 15 nmUltra-narrow emission and very high photoluminescence efficiencyImaging and sensing, mainly in vitroLead toxicity and poor stability
NV nanodiamonds5 to under 100 nmSpin coherence and magnetic sensitivityQuantum MRI and neuronal sensingCost and complex instrumentation

The ranges place semiconductor and carbon dots at 10 nm or less. Graphene dots are below 20 nm, while NV nanodiamonds extend to under 100 nm. The table reports size definitions rather than clinical performance benchmarks.

Carbon dots are less bright but metal-free, and their synthesis uses top-down and bottom-up routes. Size control, heteroatom doping, and surface functionalization tune their emission. Graphene dots combine confinement with edge states and dense surface functional groups. Black phosphorus dots require stabilization in aqueous, oxygen-rich media. Perovskite dots are placed mainly in in vitro imaging and sensing because of lead and stability limits. MoS2 and WS2 transition-metal dichalcogenide dots are under study for multimodal imaging and responsive delivery.

Confinement can also be classified by dot radius relative to the exciton Bohr radius. Strong confinement occurs when the dot radius is smaller than that radius and produces a blue shift. Confinement potentials and external fields can control refractive-index changes and nonlinear optics.

Diagnostic workflows and measurement methods

Section titled “Diagnostic workflows and measurement methods”

In vitro diagnostic systems use a biological recognition element with a physicochemical transducer. The review lists enzymes, antibodies, nucleic acids, and aptamers as recognition components. The transducer converts recognition into a measurable optical or electrochemical signal.

Quantum dots are applied in immunoassays, nucleic acid detection, cellular imaging, tumor imaging, and liquid biopsy. Multiplexed assays measure groups of proteins, nucleic acids, or metabolites in one sample. Electrochemical, optical, and microfluidic platforms support this format.

Surface functionalization, synthesis route, and biological setting change reported sensitivity and specificity. Those differences are why the review calls for standard evaluation procedures. Near-infrared quantum dots and graphene dots support deeper-tissue imaging and higher contrast. NV nanodiamonds offer a separate label-free route for neural and cardiac activity.

The paper does not give a numerical detection limit or sensitivity across platforms. Any comparison of diagnostic performance would therefore need matched assays and controls.

Therapeutic platforms and combination modes

Section titled “Therapeutic platforms and combination modes”

Quantum dots can carry drugs and genes, act as light-responsive photosensitizers, or combine imaging with treatment. Active targeting uses antibodies, peptides, folic acid, or aptamers to promote receptor-mediated uptake. Passive targeting relies on tumor EPR effects associated with leaky vasculature and poor lymphatic drainage. Stimuli such as pH, enzymes, and ligands can control release in several delivery designs.

The review also describes cationic and stimuli-responsive polymers for nucleic acid delivery. Some delivery discussion covers polymer nanocarriers generally, rather than quantum dots alone.

Photodynamic therapy uses wavelength-selected light to generate reactive oxygen species in diseased tissue. These species can cause apoptosis, necrosis, vascular shutdown, and immune attack. Photothermal therapy uses near-infrared light for local heating and tumor ablation. Heat can increase tumor permeability and support chemotherapy, immunotherapy, or radiotherapy combinations. Hybrid systems may combine photodynamic and photothermal responses.

The antimicrobial section links carbon dots to light-induced reactive oxygen species, but its body text also discusses natural products. That scope weakens the review’s focus on quantum-dot evidence.

Metal-organic frameworks provide tunable theranostic platforms with stimulus-responsive release and multimodal imaging. These are proposed mechanisms and reported advantages, not pooled clinical efficacy estimates.

NV centers contain a substitutional nitrogen atom next to a lattice vacancy. Spin-dependent fluorescence provides optical initialization and readout. They can detect weak thermal, electric, and magnetic signals under physiological conditions. The review reports high-resolution images of neuronal activity and intracellular communication. Long spin coherence and photostability support continuous monitoring of dynamic biological media.

Against MRI, the paper states that MRI requires large magnetic fields and has lower spatial resolution. This comparison is qualitative because no field strength or spatial resolution values are reported. Cost and complex instrumentation remain listed limitations for NV nanodiamonds. No in vivo sensitivity or clinical validation result is provided for the sensing platform.

The paper is a review and presents no primary experiment or pooled clinical analysis. It also gives no literature-search protocol, inclusion criteria, study count, effect-size pooling, or risk-of-bias method. Its comparisons should therefore be read as a qualitative synthesis of prior work. Progress is framed around 2021 to 2025 advances in imaging, delivery, and light-based treatment.

Heavy-metal dots can release lead or cadmium ions under physiological conditions. Protein corona formation can alter targeting, optical behavior, and surface properties unpredictably. Long-term biodistribution, accumulation, and clearance remain poorly understood. Batch variability affects carbon and graphene dots, undermining repeatability and regulatory comparison.

Theranostic systems face both diagnostic and therapeutic safety requirements. Large-scale synthesis also remains a barrier. The authors propose metal-free and biodegradable materials, multimodal platforms, microfluidics, artificial intelligence, and digital medicine. These remain suggested research directions rather than validated clinical solutions.

Material selection should follow the intended function and the risk it introduces. Semiconductor dots suit multiplexed fluorescence when narrow, stable emission is required. Carbon dots suit water-based sensing when metal-free composition matters more than maximum brightness. Graphene dots offer near-infrared heating, while black phosphorus dots require stabilization in oxygen-rich media. The review places perovskite dots in mainly in vitro imaging and sensing. NV diamond requires controlled defect quality and complex optical instrumentation for label-free functional sensing.

Evaluation should include particle size, surface functionalization, emission stability, ion release, protein corona, biodistribution, and clearance. Manufacturing assessment should also test lot-to-lot reproducibility and scale-up consistency. These criteria address the paper’s stated failure points more directly than a general claim of high sensitivity. Artificial intelligence may assist synthesis optimization and image analysis, but the review presents no clinical validation.

For the paper’s nitrogen-vacancy sensing concept, label-free neural and cardiac imaging requires diamond engineered with substitutional nitrogen next to a lattice vacancy. 6CCVD lists MPCVD-grown single-crystal diamond plates and wafers up to 125 mm in its diamond materials catalog, with thickness from 0.1 to 500 micrometers. The listed options do not specify nitrogen doping or NV-center engineering, so questions about defect-engineered requirements belong with engineering support.

View Original Abstract

Quantum nanomaterials are revolutionizing the field of precision medicine by allowing diagnostic and therapeutic procedures at the molecular and subcellular level. Of these, semiconductor quantum dots, carbon quantum dots, graphene-based quantum nanostructures, and quantum sensing platforms are characterized by their unique optical, electronic, and magnetic properties, which are a result of quantum confinement effects and other quantum phenomena. These properties, including size-dependent fluorescence, sharp emission spectra, high photostability, and ultra-high sensitivity, have made quantum nanomaterials valuable tools for bioimaging, biosensing, targeted drug delivery, and theranostic applications. In the diagnostic area, quantum dots provide ultra-high sensitivity and multiplex analysis for the detection of disease biomarkers, which is crucial for early diagnosis and molecular typing, a requirement for personalized medicine. In the field of therapeutics, quantum nanomaterials are used as carriers for drugs and genes, photosensitizers for photodynamic and photothermal therapies, and as multifunctional platforms that integrate imaging and therapeutic modalities into a single device. On the other hand, quantum sensing technologies such as nitrogen-vacancy centers in diamond and atomic magnetometers are being developed for ultra-sensitive and label-free medical imaging and functional diagnostics. Although there has been great progress in the preclinical stage, translation to the clinical stage has been impeded by several issues regarding toxicity, long-term biocompatibility, scalability of manufacturing, and regulatory issues. This review article aims to give a comprehensive and critical assessment of the types of quantum nanomaterials, their applications in diagnosis and therapy, recent progress in research, and challenges in translation. Finally, future directions are also presented, focusing on biodegradable and metal-free quantum materials, multimodal theranostic platforms, and the integration of quantum